Team

Continuous progress is driven by the passion and expertise of the ONESTX team – professionals with proven experience in biotech, research, management, and successful investment exits:

Operations

Ángel Cebolla

CEO & Founder

PhD. Pharmacist. CEO. Broad experience during 22 years as entrepreneur and founder of biotech companies. CEO of Biomedal SL, IVD company, forming multiple R&D teams, managing, and coordinating public-private research projects. He has more than a hundred publications and is co-inventor of fifteen patent applications. Biomedal has carried out one of the most successful operations in Spanish biotechnology with a self-developed product that has become the world leader in its category (Glutentox®), leading the exit of the business unit to an expanding North American company such as Hygiena. He is cofounder of several high tech companies that launched innovative products (Biomedal, Ingeniatrics, Glutenostics, etc).

Manolo Muñoz

Manuel Muñoz

CSO, Board President & Co-Founder

PhD. Founder and CSO. Manuel has more than 30 years of research experience in genetics. His main research area is the genetic regulation of longevity. He has published in high impact journals in different fields. Deeply involved in technology transfer processes by developing new technologies for the industrial application. He is the author of seven patents (3 licensed), two industrial secrets and promoter of two biotechnology companies: CEPA S.L. and Olavide Neuron STX (ONESTX). Professor at University Pablo de Olavide.

Viñas Andrés Simón

Chief Clinical Operations Officer

Neuroscientist (PhD) with a broad experience in the basic, preclinical and clinical research. In charge of projects related to bioanalysis, biomarkers, neuroimaging, pharmacogenetic and -omics. Within the last 25 years she has performed different roles in the field of clinical research. Since 2006 to 2021, first in Biotech (Noscira) and later in large CRO (Syneos Health), she has been mainly involved in preclinical and clinical development projects in neurodegenerative diseases (Alzheimer, Parkinson and PSP). Former Director of Clinical Operations and Development at Peaches Biotech. She joins ONESTX to lead the drug development and clinical trial program.

Sandra Gavaldá

Chief Operations Officer

PhD, PMP. Researcher with a molecular biology background in public institutions and private companies. Leading R&D projects at bioethanol production industry and biomedicine (ATMPs) companies in the last 10 years. Coordinator of multidisciplinary teams in the tech transfer activities from bench to clinical phase.

Daniel Zamanillo

Head of Research and Preclinical Development

PhD. Daniel is an experienced pharmacology and neuroscience researcher with over 25 years in preclinical drug development. He currently serves as Head of Preclinical Pharmacology at ONESTX, leading innovative projects in neurological disorders and pain management. Previously, he held senior roles at WeLab Barcelona and ESTEVE, where he specialized in in vivo pharmacology and analgesia research. Daniel holds a PhD in Neuroscience from Universidad de León and has a strong track record in translational research aimed at improving therapeutic strategies for chronic pain.

M. Luz Bellido

Head of Innovation Management & QA

Accomplished Pharma and Biotech Executive (PhD, MBA) with over 20 years of leadership driving innovation management, drug discovery, and preclinical development across spin-offs and startups. Proven track record in translating cutting-edge science into viable therapeutic programs, specializing in New Chemical Entities (NCEs) for inflammatory and neurodegenerative diseases. Combines deep scientific rigor with comprehensive business acumen, offering extensive expertise in CDMO operations, strategic biotech project management, licensing, and financing.

Dr. Carmen Navarrón

Project Manager of Biomarkers and Clinical Trials

Accomplished Project Manager specializing in translational neuroimaging and fluid biomarkers for complex clinical trials. Building on her background at Alzheimer’s Research UK, Dr. Carmen Navarrón seamlessly bridges early discovery and clinical application, expertly driving biomarker development, clinical operations, and trial execution across neurodegenerative disease programs.

Basilio Sáez

Finance

Accomplished Corporate Finance Director with a proven track record in financial governance, strategic planning, and compliance at leading biotech firms like Biomedal. Basilio Sáez excels at establishing robust financial controls, optimizing capital allocation, and driving sustainable fiscal strategy to support corporate growth and stakeholder value.

Advisory Board

Mercè Boada

MD, PhD

Dr. Mercè Boada is an internationally recognized neurologist specializing in neurodegenerative diseases. As the Co-founder and Medical Director of Fundación ACE, she has spearheaded numerous clinical and research projects focused on Alzheimer’s disease. Her career exemplifies a blend of scientific excellence, leadership in clinical care, and a deep commitment to innovation in cognitive health.

Teodoro del Ser

MD

Dr. Teodoro del Ser is a neurologist and the Coordinator of the Clinical Group at Fundación CIEN. With a strong multidisciplinary background spanning medicine, psychology, and sociology, he brings extensive experience in translational research and the design of clinical trials for dementias and other neurodegenerative pathologies. His profile integrates profound clinical knowledge with a strategic vision for biomedical research.

John Normanton

PhD

Dr. John R. Normanton is an experienced executive and consultant in the biotechnology and pharmaceutical sectors, holding a Ph.D. in Pharmacology from the University of Leeds. He serves as the Managing Director of Oxandia Limited (since 2006) and is the Co-Founder and Chief Executive of Gliagenesis Limited. His extensive expertise includes a specialized focus on the development of endocrine therapies, having served as the Managing Director of Estryx Pharma Limited. In this role, he led the company’s strategy focused on Steroid Sulfatase Inhibitors (STSis), including the development of agents such as the Dual Aromatase-Sulfatase Inhibitor (DASI), an area in which the company has nearly two decades of involvement. His profile successfully combines scientific rigor with strategic direction in innovative drug development.

Pablo Ortiz

MD, PhD

Pablo Ortiz is a seasoned consultant specializing in strategy and business development within the biotechnology sector. With a strong foundation in medicine (MD, PhD, UAM) and a significant 25-year tenure at Boehringer Ingelheim, he has a proven track record as a successful biotech executive, notably as CEO of Digna Biotech and OWL Metabolomics. Under his leadership, he secured significant investment, advanced 4 products to clinical phase, and achieved CE marking for the first NASH diagnostic product based on metabolomics technology. His career connects scientific rigor (including 35 high-impact publications) with strategic management and market-entry success.

José Javier Lucas

PhD

Dr. José Javier Lucas is a Senior Researcher at the Spanish National Research Council (CSIC) at the «Severo Ochoa» Center for Molecular Biology. Recognized for his work on the molecular mechanisms of neurological disorders, he has led national and international projects in the field of neurobiology. His scientific contributions and institutional experience establish him as a leading authority in biomedical research.

Javier S. Burgos

PhD

Dr. Javier S. Burgos is a Distinguished Researcher at Universitat Jaume I and an expert in biomedicine and technology transfer. He has led research groups in biotechnology and participated in multiple R&D projects focused on healthcare innovation. His experience combines scientific management, technological development, and leadership in applied research.

Francisco León

MD, PhD

Dr. F. León is a physician-scientist, immunologist, and seasoned biotech entrepreneur with over two decades of global experience in drug discovery, clinical development, and corporate strategy. As Co-Founder and former Chief Scientific Officer of Provention Bio, he played a pivotal role in advancing breakthrough immunotherapies for autoimmune and inflammatory diseases. An expert in translational immunology, he has held leadership positions at major pharmaceutical companies including Janssen, Bristol Myers Squibb, and MedImmune, as well as co-founding Celimmune. Currently serving as CEO and Founder of Tolerance Bio, Dr. León continues to drive clinical innovation, venture financing, and strategic partnerships across the life sciences industry.

Mercedes Pérez Jiménez

Founder and Aging processes advisor

PhD. Founder. Expert in biology and genetics of aging. International experience at CNRS, where she contributed to broadening scientific knowledge on germline development in nematodes. Her current line of research is the use of steroid sulfatase inhibition for the expansion of life span and to inactivate neurodegeneration in animal models. Co-inventor together with Manuel Muñoz and Ángel Carrión of patents that back the project. Associate researcher at University Pablo de Olavide.

Ángel Manuel Carrión

Founder and Mammal model advisor

PhD. Founder. In the last 22 years he applies a multidisciplinary approach to the fields of nociception and cognitive processes, from behavior to its molecular basis. He leads a pioneering research group in describing the role of steroid sulfatase inhibitors in neurodegenerative diseases, in addition to the role of aging in these pathologies. Professor at the Pablo de Olavide University.

Clinical & academic network

Strong operational partnerships with Enroll-HD, Ace Alzheimer Center Barcelona, CIEN Foundation, CSIC, and Universidad Pablo de Olavide, ensuring rigorous clinical trial execution.

Other advisors

Our core team is complemented by an extended network of senior advisors and domain experts spanning EU & US Regulatory Affairs (EMA/FDA), Drug Manufacturing & Quality Control (CMC/GMP), Global Patent Strategy (IP), and Cross-Border Business Development & Investor Relations.

Investors